Avalon GloboCare Corp. announced that it has deployed a breakthrough fusion gene map technology to be used for the goal of developing companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients. In collaboration with the Lu Daopei Institute of Hematology, a fusion gene map database from over 1,000 patients with leukemia was established and the results were previously published in the Blood Cancer Journal.

Fusion genes are important genetic abnormalities in leukemia. Using advanced gene sequencing technology, called "Whole Transcriptome Sequencing" (WTS), multiple previously unknown fusion genes were identified which may potentially establish novel diagnostic and therapeutic targets.